Optimizing Patient Outcomes - Metastatic Castration-Resistant Prostate Cancer: Systemic Therapy Updates
It is important to stay up to date with the latest therapy options available, review the latest mCRPC systemic therapy recommendations, and understand the data behind them.
Category
  • Prostate Cancer
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Event date April 28, 2025
Cost $0.00
NCCN Tumor Boards: T-Cell Engager Therapy for Diffuse Large B-Cell Lymphoma: Bispecific Antibodies for Relapsed/Refractory Disease
T-cell engager therapy with bispecific antibodies is emerging as a promising treatment option for patients with heavily pretreated DLBCL. Careful monitoring of adverse events and implementing appropriate supportive care strategies is important to maximize the clinical benefit.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Live Webinar
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Event date April 30, 2025
Cost $0.00